Literature DB >> 18180400

Endothelial dysfunction and elevated blood pressure in MAS gene-deleted mice.

Ping Xu1, Andrey C Costa-Goncalves, Mihail Todiras, Luiza A Rabelo, Walkyria O Sampaio, Marina M Moura, Sergio Sousa Santos, Friedrich C Luft, Michael Bader, Volkmar Gross, Natalia Alenina, Robson A S Santos.   

Abstract

Mas codes for a G protein-coupled receptor that is implicated in angiotensin-(1-7) signaling. We studied the cardiovascular phenotype of Mas-deficient mice backcrossed onto the FVB/N genetic background using telemetry and found that they exhibit higher blood pressures compared with controls. These Mas(-/-) mice also had impaired endothelial function, decreased NO production, and lower endothelial NO synthase expression. Reduced nicotinamide-adenine dinucleotide phosphate oxidase catalytic subunit gp91(phox) protein content determined by Western blotting was higher in Mas(-/-) mice than in controls, whereas superoxide dismutase and catalase activities were reduced. The superoxide dismutase mimetic, Tempol, decreased blood pressure in Mas(-/-) mice but had a minimal effect in control mice. Our results show a major cardiovascular phenotype in Mas(-/-) mice. Mas-deletion results in increased blood pressure, endothelial dysfunction, and an imbalance between NO and reactive oxygen species. Our animals represent a promising model to study angiotensin-(1-7)-mediated cardiovascular effects and to evaluate Mas agonistic compounds as novel cardioprotective and antihypertensive agents based on their beneficial effects on endothelial function.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18180400     DOI: 10.1161/HYPERTENSIONAHA.107.102764

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  69 in total

Review 1.  International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].

Authors:  Sadashiva S Karnik; Hamiyet Unal; Jacqueline R Kemp; Kalyan C Tirupula; Satoru Eguchi; Patrick M L Vanderheyden; Walter G Thomas
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

Review 2.  The vasoprotective axes of the renin-angiotensin system: Physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases.

Authors:  Xiao C Li; Jianfeng Zhang; Jia L Zhuo
Journal:  Pharmacol Res       Date:  2017-06-12       Impact factor: 7.658

Review 3.  New physiological concepts of the renin-angiotensin system from the investigation of precursors and products of angiotensin I metabolism.

Authors:  Carlos M Ferrario
Journal:  Hypertension       Date:  2009-12-21       Impact factor: 10.190

Review 4.  Macrophages in neuroinflammation: role of the renin-angiotensin-system.

Authors:  Anna Hammer; Johannes Stegbauer; Ralf A Linker
Journal:  Pflugers Arch       Date:  2017-02-11       Impact factor: 3.657

Review 5.  Recombinant human angiotensin-converting enzyme 2 as a new renin-angiotensin system peptidase for heart failure therapy.

Authors:  Gavin Y Oudit; Josef M Penninger
Journal:  Curr Heart Fail Rep       Date:  2011-09

6.  Differential effects of Mas receptor deficiency on cardiac function and blood pressure in obese male and female mice.

Authors:  Yu Wang; Robin Shoemaker; David Powell; Wen Su; Sean Thatcher; Lisa Cassis
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-12-16       Impact factor: 4.733

7.  Inhibitory effects of angiotensin-(1-7) on the nerve stimulation-induced release of norepinephrine and neuropeptide Y from the mesenteric arterial bed.

Authors:  Mirnela Byku; Heather Macarthur; Thomas C Westfall
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-11-20       Impact factor: 4.733

8.  Predisposition to atherosclerosis and aortic aneurysms in mice deficient in kinin B1 receptor and apolipoprotein E.

Authors:  Vanessa F Merino; Mihail Todiras; Marcelo A Mori; Vicência M T Sales; Raphael G Fonseca; Vera Saul; Katja Tenner; Michael Bader; João B Pesquero
Journal:  J Mol Med (Berl)       Date:  2009-07-18       Impact factor: 4.599

9.  Angiotensin-converting enzyme 2: a new target for neurogenic hypertension.

Authors:  Yumei Feng; Huijing Xia; Robson A Santos; Robert Speth; Eric Lazartigues
Journal:  Exp Physiol       Date:  2009-11-18       Impact factor: 2.969

10.  Inducible transgenic rat model for diabetes mellitus based on shRNA-mediated gene knockdown.

Authors:  Katarina Kotnik; Elena Popova; Mihail Todiras; Marcelo A Mori; Natalia Alenina; Jost Seibler; Michael Bader
Journal:  PLoS One       Date:  2009-04-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.